指南与共识治疗药物监测与药物基因组学药物相互作用药物不良反应与药物警戒

CPIC指南药物药物基因组学检测的成本效果系统综述

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.
指南 / 共识 · Clin Pharmacol Ther · 2022-10-09

该系统综述纳入108项研究评估39种药物的药物基因组学(PGx)检测成本效果,其中77项(71%)显示PGx检测具有成本效果(48项)或节省成本(29项);氯吡格雷相关研究最多(23篇,22篇支持),HLA检测相关26篇中15篇支持。多数研究支持PGx检测,但抢先检测和多基因检测数据有限。

要点

  • 多数CPIC指南药物的PGx检测具成本效果或节省成本。
  • 氯吡格雷PGx检测成本效果证据最充分(23篇中22篇支持)。
  • 抢先检测和多基因检测的成本效果数据有限。

核心结论

  • 多数评估CPIC指南药物PGx检测成本效果的研究支持PGx检测具有成本效果或节省成本。

研究设计与样本

  • 系统综述检索多个生物医学文献数据库至2021年6月,纳入比较PGx指导与非指导治疗的全篇文章,共108项研究评估39种药物。
  • 使用健康经济研究质量(QHES)量表(0-100分)评估研究稳健性,中位QHES评分为91分(范围48-100),反映高质量研究。

主要发现

  • 108项研究中77项(71%)显示PGx检测具成本效果(48项)或节省成本(29项);21项(20%)不具成本效果;10项(9%)不确定。
  • 氯吡格雷相关文章最多(23篇),其中22篇显示成本效果或节省成本;华法林相关16篇中7篇显示成本效果或节省成本。
  • 26项评估HLA检测的研究(阿巴卡韦8项、别嘌醇10项、卡马西平/苯妥英8项)中15项显示成本效果或节省成本。
  • 11篇抗抑郁药相关文章中9篇显示成本效果或节省成本。

临床怎么用

  • 临床可优先参考证据充分的药物(如氯吡格雷)开展PGx检测以优化成本效果。

局限性

  • 抢先检测和多基因检测跨疾病状态的成本效果数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this study was to evaluate the evidence on cost-effectiveness of pharmacogenetic (PGx)-guided treatment for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A systematic review was conducted using multiple biomedical literature databases from inception to June 2021. Full articles comparing PGx-guided with nonguided treatment were included for data extraction. Quality of Health Economic Studies (QHES) was used to assess robustness of each study (0-100). Data are reported using descriptive statistics. Of 108 studies evaluating 39 drugs, 77 (71%) showed PGx testing was cost-effective (CE) (N = 48) or cost-saving (CS) (N = 29); 21 (20%) were not CE; 10 (9%) were uncertain. Clopidogrel had the most articles (N = 23), of which 22 demonstrated CE or CS, followed by warfarin (N = 16), of which 7 demonstrated CE or CS. Of 26 studies evaluating human leukocyte antigen (HLA) testing for abacavir (N = 8), allopurinol (N = 10), or carbamazepine/phenytoin (N = 8), 15 demonstrated CE or CS. Nine of 11 antidepressant articles demonstrated CE or CS. The median QHES score reflected high-quality studies (91; range 48-100). Most studies evaluating cost-effectiveness favored PGx testing. Limited data exist on cost-effectiveness of preemptive and multigene testing across disease states.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Morris SA, Alsaidi AT, Verbyla A, et al. Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review. Clin Pharmacol Ther. 2022. PMID: 36149409. doi:10.1002/cpt.2754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。